DK0973546T3 - Stabiliserede formuleringer med human papillomavirus - Google Patents

Stabiliserede formuleringer med human papillomavirus

Info

Publication number
DK0973546T3
DK0973546T3 DK98915319T DK98915319T DK0973546T3 DK 0973546 T3 DK0973546 T3 DK 0973546T3 DK 98915319 T DK98915319 T DK 98915319T DK 98915319 T DK98915319 T DK 98915319T DK 0973546 T3 DK0973546 T3 DK 0973546T3
Authority
DK
Denmark
Prior art keywords
human papillomavirus
stabilized formulations
formulations
hpv
polysorbate
Prior art date
Application number
DK98915319T
Other languages
English (en)
Inventor
Gautum Sanyal
David B Volkin
Li Shi
Original Assignee
Merck & Co Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB9709351.2A external-priority patent/GB9709351D0/en
Application filed by Merck & Co Inc filed Critical Merck & Co Inc
Application granted granted Critical
Publication of DK0973546T3 publication Critical patent/DK0973546T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5258—Virus-like particles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/20011—Papillomaviridae
    • C12N2710/20022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/20011—Papillomaviridae
    • C12N2710/20023—Virus like particles [VLP]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/20011—Papillomaviridae
    • C12N2710/20034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Virology (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Mycology (AREA)
  • Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Oncology (AREA)
  • Biophysics (AREA)
  • Biotechnology (AREA)
  • Communicable Diseases (AREA)
  • Biomedical Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Gastroenterology & Hepatology (AREA)
  • General Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Plant Substances (AREA)
DK98915319T 1997-04-08 1998-04-07 Stabiliserede formuleringer med human papillomavirus DK0973546T3 (da)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US4280897P 1997-04-08 1997-04-08
GBGB9709351.2A GB9709351D0 (en) 1997-05-07 1997-05-07 Stabilized human papillomavirus formulations
PCT/US1998/006825 WO1998044944A2 (en) 1997-04-08 1998-04-07 Stabilized human papillomavirus formulations

Publications (1)

Publication Number Publication Date
DK0973546T3 true DK0973546T3 (da) 2004-06-28

Family

ID=26311501

Family Applications (1)

Application Number Title Priority Date Filing Date
DK98915319T DK0973546T3 (da) 1997-04-08 1998-04-07 Stabiliserede formuleringer med human papillomavirus

Country Status (18)

Country Link
EP (1) EP0973546B1 (da)
JP (1) JP4598201B2 (da)
KR (1) KR20010006169A (da)
CN (1) CN1259051A (da)
AT (1) ATE261734T1 (da)
AU (1) AU739829B2 (da)
CA (1) CA2286294A1 (da)
DE (1) DE69822452T2 (da)
DK (1) DK0973546T3 (da)
EE (1) EE9900612A (da)
ES (1) ES2216280T3 (da)
IL (1) IL132201A0 (da)
NO (1) NO994879L (da)
NZ (1) NZ500028A (da)
PL (1) PL336715A1 (da)
PT (1) PT973546E (da)
SK (1) SK138199A3 (da)
WO (1) WO1998044944A2 (da)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AUPP765398A0 (en) * 1998-12-11 1999-01-14 University Of Queensland, The Treatment of papillomavirus infections
ATE413188T1 (de) 1999-02-05 2008-11-15 Merck & Co Inc Menschliche papillomavirus impfstoff- formulierungen
US6245568B1 (en) * 1999-03-26 2001-06-12 Merck & Co., Inc. Human papilloma virus vaccine with disassembled and reassembled virus-like particles
DE10137102A1 (de) 2001-07-30 2003-02-27 Deutsches Krebsforsch Polyvalente Vakzine gegen durch Papillomaviren verursachte Erkrankungen, Verfahren zu deren Herstellung und deren Verwendung
GB0206360D0 (en) 2002-03-18 2002-05-01 Glaxosmithkline Biolog Sa Viral antigens
TW200806315A (en) * 2006-04-26 2008-02-01 Wyeth Corp Novel formulations which stabilize and inhibit precipitation of immunogenic compositions
EP2601969B1 (en) 2006-09-29 2016-03-30 Takeda Vaccines, Inc. Norovirus vaccine formulations
CN104740624B (zh) 2007-09-18 2018-04-24 武田疫苗股份有限公司 赋予针对诺如病毒的保护性免疫应答的疫苗
WO2009092113A2 (en) * 2008-01-19 2009-07-23 Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Methods and compositions for the delivery of vaccines to disrupted epithelium
SG190937A1 (en) * 2010-12-14 2013-07-31 Glaxosmithkline Biolog Sa Mycobacterium antigenic composition
CN102085354A (zh) * 2010-12-30 2011-06-08 重庆大学 一种治疗人乳头瘤病毒16型引发的肿瘤的多肽药物
PH12014500093A1 (en) 2011-07-11 2014-03-17 Takeda Vaccines Inc Parenteral norovirus vaccine formulations
CN105039358B (zh) * 2013-12-03 2020-02-28 北京康乐卫士生物技术股份有限公司 58型重组人乳头瘤病毒病毒样颗粒及其制备方法
EP3191505A2 (en) * 2014-09-11 2017-07-19 Cadila Healthcare Limited Superior human papilloma virus antigens with superior immunological properties and vaccine containing it
CN106701797B (zh) * 2015-08-12 2021-06-15 北京康乐卫士生物技术股份有限公司 31型重组人乳头瘤病毒病毒样颗粒及其制备方法
CN106399329B (zh) * 2015-08-12 2021-06-11 北京康乐卫士生物技术股份有限公司 33型重组人乳头瘤病毒病毒样颗粒及其制备方法
CN108201623A (zh) * 2016-12-19 2018-06-26 无锡鑫连鑫生物医药科技有限公司 人乳头瘤病毒重组四价疫苗、其制备方法及其应用
JP7688576B6 (ja) * 2018-11-28 2025-07-04 ザ ジェネラル ホスピタル コーポレイション 共生ウイルスに対するｔ細胞指向性抗がんワクチン

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2949031A1 (de) * 1978-12-15 1980-07-17 Sandoz Ag Vakzine
US4606918A (en) * 1983-08-22 1986-08-19 Syntex (U.S.A.) Inc. Polyoxypropylene-polyoxyethylene block polymer based adjuvants
JPS63239234A (ja) * 1988-01-14 1988-10-05 Green Cross Corp:The ワクチン製剤
JPH085803B2 (ja) * 1988-11-10 1996-01-24 武田薬品工業株式会社 日本脳炎ワクチンの製造法
JP3814290B2 (ja) * 1993-12-09 2006-08-23 エスクナー，ハインリッヒ 抗原用のアジュバントおよびその製法ならびに用途
AUPM566794A0 (en) * 1994-05-17 1994-06-09 University Of Queensland, The Process and product
AR004464A1 (es) * 1994-11-14 1998-12-16 Merck Sharp & Dohme Un metodo para producir una proteina de capside de papilomavirus
IL117459A (en) * 1995-03-22 2005-11-20 Merck & Co Inc Dna encoding human papillomavirus type 18
IL117591A0 (en) * 1995-03-30 1996-07-23 Merck & Co Inc Synthetic DNA encoding human papillomavirus type 11 L1 protein
US5718904A (en) * 1995-06-02 1998-02-17 American Home Products Corporation Adjuvants for viral vaccines

Also Published As

Publication number Publication date
NZ500028A (en) 2001-08-31
DE69822452T2 (de) 2006-04-20
EP0973546B1 (en) 2004-03-17
PT973546E (pt) 2004-06-30
NO994879L (no) 1999-12-07
PL336715A1 (en) 2000-07-03
IL132201A0 (en) 2001-03-19
DE69822452D1 (de) 2004-04-22
EE9900612A (et) 2000-08-15
CN1259051A (zh) 2000-07-05
WO1998044944A3 (en) 1998-12-30
ATE261734T1 (de) 2004-04-15
AU739829B2 (en) 2001-10-18
AU6953398A (en) 1998-10-30
JP2001519814A (ja) 2001-10-23
KR20010006169A (ko) 2001-01-26
ES2216280T3 (es) 2004-10-16
SK138199A3 (en) 2000-06-12
EP0973546A2 (en) 2000-01-26
CA2286294A1 (en) 1998-10-15
JP4598201B2 (ja) 2010-12-15
WO1998044944A2 (en) 1998-10-15
NO994879D0 (no) 1999-10-07

Similar Documents

Publication Publication Date Title
NO994879D0 (no) Stabiliserte humane papillomavirusformuleringer
NO2025027I1 (no) Pharmaceutical mixture or association that includes as active ingredients: (1) ceftazidime or a salt thereof, and (2) avibactam or a pharmaceutically acceptable salt thereof - forlenget.
TR200302105T4 (tr) Siklosporin, hiyalüronik asit ve polisorbat içeren göz formülasyonları.
CY1113609T1 (el) ΔΙΑΛΥΤΟΤΗΤΑ ΙFΝ-ΒΗΤΑ-1b ΣΕ ΔΙΑΛΥΜΑΤΑ ΧΛΩΡΙΟΥΧΟΥ ΝΑΤΡΙΟΥ
ATE245033T1 (de) Verwendung von metallionen chelatoren zur stabilisierung von interferon-enthaltenden pharmazeutischen zubereitungen
NO20054324L (no) Anvendelse av ranolazin og minst ett pH-avhengig bindemiddel for fremstilling av ranolazinpreparater med depotvirkning
IS4067A (is) PEG-Interferonafleiður, aðferð til framleiðslu þeirra, og notkunar sem lyfja
EP0731712A4 (en) PHYSIOLOGICALLY STABLE COMPOSITIONS OF BUTYRIC ACID, SALTS AND BUTYRIC ACID DERIVATIVES AS ANTINEOPLASTIC AGENTS
DE60137122D1 (de) Winkelähnlichkeitsoperator mit verallgemeinertem lensing
ATE206308T1 (de) Arzneizusammensetzungen enthaltend ein bakterizides permeabilität erhöhendes protein und ein tensid
DE69636953D1 (de) Lyophilisierte hgf-zubereitungen
PL346764A1 (en) New oral formulation for 5-ht4
BR0110290A (pt) Preparação lìquida estabilizada
MXPA02005563A (es) Formulacion estable de interferon en solucion acuosa, metodo de preparacion y usos de la misma.
CA2060560A1 (en) Method for insuring adequate intracellular glutathione in tissue
SE9402880D0 (sv) New peptide derivatives
MXPA05009135A (es) Formulaciones liquidas de las proteinas de union del factor necrosis del tumor.
BR0008952A (pt) Composição de preparação de iodo
UY27373A1 (es) Formulaciones de interferón beta-humano
PT1091740E (pt) Preparacoes aquosas semi-solidas para administracao oral de toltrazuril-sulfona
ATE341339T1 (de) Zusammensetzungen von rekombinanten papillomavirus vakzinen
ATE301453T1 (de) Injizierbare arzneiformulierungen von partricin derivaten
EA199900915A1 (ru) Стабилизированные композиции вируса папилломы человека
ES2073063T3 (es) Formulaciones galenicas acuosas de eritropoyetina y su uso.
RU2003124254A (ru) Косметическое средство для ухода за кожей лица и шеи